Session Information
-
WCLC 2020
2020 World Conference on Lung Cancer
Conference Program for the 2020 World Conference on Lung Cancer in Singapore
Presentation Date(s):- January 28 - 31, 2021
- Total Presentations: 1597
All times listed are in Singapore time (GMT+8)
PL - Plenary
PS - Presidential Symposium
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
FP - Featured Posters
P - Posters
IS - Industry Symposium
JICC - Joint IASLC-CAALC-CSCO Session
January 28 Thu
Jan 28 Friday
January 29 Fri
Jan 29 Saturday
January 30 Sat
Jan 30 Sunday
January 31 Sun
Jan 31
-
+
P75 - Immunotherapy (Phase II/III Trials) - Misc. Topics
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
-
+
P75.20 - Outcomes of Lung Cancer Patients with Leptomeningeal Metastases Following Immune Checkpoint Inhibitor Treatments: A Pooled Analysis
00:00 - 00:00 | Presenter: meimei Zheng
- Abstract
Loading...
-
+
P76 - Targeted Therapy - Clinically Focused - EGFR
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Targeted Therapy - Clinically Focused
-
+
P76.19 - Clinical Outcomes of Lung Cancer Patients Who Acquired EGFR T790M/in trans-C797S Mutations After Resistance to Osimertinib
00:00 - 00:00 | Presenter: Chang Lu
- Abstract
Loading... -
+
P76.60 - FLAIR: Phase II Study of Osimertinib plus Bevacizumab versus Osimertinib in Advanced NSCLC Patients with EGFR L858R Mutation
00:00 - 00:00 | Presenter: Qing Zhou
- Abstract
Loading... -
+
P76.67 - Safety and Efficacy of First-Line Dacomitinib in Advanced Non-Small Cell Lung Cancer by EGFR Mutation SUBtype in ARCHER 1050
00:00 - 00:00 | Presenter: Adam Pluzanski
- Abstract
Loading... -
+
P76.78 - Evaluation of the Development of Brain Metastases in Patients Treated with Dacomitinib or Gefitinib from ARCHER 1050 Study
00:00 - 00:00 | Presenter: Qing Zhou
- Abstract
Loading... -
+
P76.81 - Primary Resistance to EGFR-TKIs in Lung Adenocarcinoma harboring EGFR–RAD51 Fusion: A Brief Report
00:00 - 00:00 | Presenter: Han-Min Wang
- Abstract
Loading... -
+
P76.96 - START: Real-world Prospective Study on Sequential Therapy with First-Line Afatinib in Chinese Patients with EGFRm+ Advanced NSCLC
00:00 - 00:00 | Presenter: Jianying Zhou
- Abstract
Loading...
-
+
P78 - Immunotherapy (Phase II/III Trials) - Immune Checkpoint Inhibitor Single Agent
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
-
+
P78.03 - Camrelizumab Umbrella Trial Based on PD-L1 Expression: OS and PFS2 in Pre-Treated Advanced NSCLC
00:00 - 00:00 | Presenter: Cheng Huang
- Abstract
Loading...
-
+
P85 - Targeted Therapy - Clinically Focused - MET
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Targeted Therapy - Clinically Focused
-
+
P85.02 - NGS could not Replace FISH Regarding to MET Amplification as an Optimal Biomarker
00:00 - 00:00 | Presenter: lunxi Peng
- Abstract
Loading... -
+
P85.07 - Neutrophils Counts Deregulated by C-met TKIs and the Variation Predicts Treatment Response in NSCLC
00:00 - 00:00 | Presenter: Xiao-Rong Yang
- Abstract
Loading...
-
+
MA01 - Novel Systemic Treatment in NSCLC
- 11:45 - 12:45
- 1/29/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Mini Oral
- Track: Antibody Drug Conjugates, Novel Therapeutics and Cytotoxics
-
+
MA01.10 - MDM2 Inhibitor APG-115 Suppresses Cell Proliferation and Tumor Growth in Preclinical Models Of NSCLC Harboring STK11 Mutations
12:20 - 12:25 | Presenter: Hao Sun
- Abstract
Loading...
-
+
MA02 - Technological Advances in Diagnostics, Imaging and Therapeutics for Lung Cancer
- 14:15 - 15:15
- 1/29/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Mini Oral
- Track: Diagnostics and Interventional Pulmonology
-
+
MA02.08 - Computed Tomography Attenuation Value as Considerable Predictor for Malignancy in Clinical T1 Lung Adenocarcinoma
14:30 - 14:35 | Presenter: Zhen-Bin Qiu
- Abstract
Loading...
-
+
MA04 - Health Policy and the Real World
- 16:45 - 17:45
- 1/29/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Mini Oral
- Track: Health Services Research/Health Economics
-
+
MA04.06 - Clinical Characteristics and Outcomes in Advanced KRAS Mutant NSCLC – A Multi-Centre Collaboration in Asia (ATORG-005)
17:15 - 17:20 | Presenter: Jiyun Lee
- Abstract
Loading...
-
+
OA06 - Updates on EGFR Targeted Perioperative Therapy and Precision Adjuvant Chemotherapy
- 16:45 - 17:45
- 1/29/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Oral
- Track: Early Stage/Localized Disease
-
+
OA06.03 - Patient-Reported Outcomes from ADAURA: Osimertinib as Adjuvant Therapy in Patients with Resected EGFR Mutated (EGFRm) NSCLC
16:45 - 16:55 | Presenter: Margarita Majem
- Abstract
Loading... -
+
OA06.04 - Postoperative Chemotherapy Use and Outcomes from ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR Mutated NSCLC
16:55 - 17:05 | Presenter: Yi-long Wu
- Abstract
Loading...
-
+
MA12 - Controversies Old and New
- 16:45 - 17:45
- 1/31/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Mini Oral
- Track: Small Cell Lung Cancer/NET
-
+
MA12.08 - Chemotherapy plus EGFR TKIs or Bevacizumab versus Chemotherapy Alone in SCLC-Transformed EGFR-Mutant Lung Adenocarcinoma
17:10 - 17:15 | Presenter: Chan-Yuan Zhang
- Abstract
Loading...
-
+
MA13 - Tumor Biology: Focus on EGFR Mutation, DNA Repair and Tumor Microenvironment
- 16:45 - 17:45
- 1/31/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Mini Oral
- Track: Tumor Biology and Systems Biology - Basic and Translational Science
-
+
MA13.09 - Heterogeneous Genomic Evolution and Immune Microenvironments in Metastatic Lung Cancer
17:30 - 17:35 | Presenter: Wen-Fang Tang
- Abstract
Loading...
first
prev
